EORTC response criteria for 18F-FDG PET/CT.
|CMR||Complete resolution of [18F]-FDG uptake within the tumour volume so that it was indistinguishable from surrounding normal tissue|
|PMR||Reduction of a minimum of 15 ± 25% in tumour 18F-FDG SUV after one cycle of chemotherapy and greater than 25% after more than one treatment cycle|
|SMD||Increase in tumour 18F-FDG SUV of less than 25% or a decrease of less than 15% and no visible increase in extent of 18F-FDG tumour uptake (20% in the longest dimension)|
|PMD||Increase in 18F-FDG tumour SUV of greater than 25% within the tumour region defined on the baseline scan and visible increase in the extent of 18F-FDG tumour uptake (20% in the longest dimension) or the appearance of new 18F-FDG uptake in metastatic lesions|